Pharmaceuticals

Myelodysplastic Syndrome (MDS) Drugs Market Outlook Indicating Growth Toward $5.56 Billion by 2030

March 23, 2026March 23, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Myelodysplastic Syndrome (MDS) Drugs Market Over The 2026–2030 Period?

The market for myelodysplastic syndrome (MDS) drugs has experienced significant expansion in recent years. It is projected to grow from $3.7 billion in 2025 to $3.98 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. The historical increase can be ascribed to elements such as elevated diagnosis rates of bone marrow disorders, the accessibility of hypomethylating agents, a proliferation of oncology treatment centers, increased adoption of supportive transfusion therapies, and enhanced understanding of the disease.

The myelodysplastic syndrome (mds) drugs market size is anticipated to demonstrate robust growth over the next few years. It is projected to expand to $5.56 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.7%. This growth during the forecast period is primarily driven by the increasing creation of novel immunomodulatory drugs, the growing acceptance of precision medicine in hematology, the expansion of clinical trial pipelines, a heightened focus on enhancing patient quality of life, and rising healthcare expenditure on rare diseases. Key trends expected in the forecast duration involve the increasing implementation of targeted therapeutic regimens, the rising uptake of oral and parenteral combination therapies, an increased emphasis on personalized treatment strategies, the broadening of supportive care interventions, and improved tracking of treatment outcomes.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13043&type=smp

Which Major Factors Are Driving The Expansion Of The Myelodysplastic Syndrome (MDS) Drugs Market?

The growing occurrence of myeloid leukemia is anticipated to boost the expansion of the myelodysplastic syndrome (MDS) drug treatment market in the future. Myeloid leukemia is a form of cancer that originates in the bone marrow, impacting cells crucial for producing various types of blood cells. Myelodysplastic syndrome (MDS) drugs are designed to enhance bone marrow function by addressing the underlying cause of leukemia, thereby decreasing the likelihood of complications associated with low blood cell counts, reducing the necessity for chemotherapy and transplants, and improving survival rates for individuals with myelodysplastic syndrome (MDS). For instance, projections from the American Cancer Society, a US-based voluntary health organization, indicated that in January 2023, approximately 20,380 cases and 11,310 deaths from acute myeloid leukemia (AML) would occur in adults throughout 2023. Consequently, the rising instances of myeloid leukemia are propelling the myelodysplastic syndrome (MDS) drug market.

How Is The Myelodysplastic Syndrome (MDS) Drugs Market Segmented Across Key Categories?

The myelodysplastic syndrome (mds) drugs market covered in this report is segmented –

1) By Drug Type: Chemotherapy, Immunomodulatory Drugs

2) By Route Of Administration: Oral, Parenteral

3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts

4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Chemotherapy: Hypomethylating Agents, Cytotoxic Agents

2) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide

Which Upcoming Trends Are Expected To Influence The Myelodysplastic Syndrome (MDS) Drugs Market?

Leading companies in the myelodysplastic syndrome (MDS) drugs market are concentrating on developing innovative products, such as targeted therapy, to enhance patient outcomes, fulfill specific customer needs, and integrate effectively into the existing ecosystem. Targeted therapy for myelodysplastic syndromes (MDS) involves using drugs that specifically identify and attack genetic mutations or molecular abnormalities within cancer cells, aiming to improve results by selectively destroying abnormal cells while minimizing harm to healthy tissue. For example, in October 2023, the U.S. Food and Drug Administration (FDA) granted approval for Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) who have an isocitrate dehydrogenase-1 (IDH1) mutation. The efficacy of Tibsovo for this new indication was determined in an open-label, single-arm, multicenter study that included 18 adult patients suffering from relapsed or refractory MDS with an IDH1 mutation.

Who Are The Dominant Players Shaping The Myelodysplastic Syndrome (MDS) Drugs Market Landscape?

Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.

Read the full myelodysplastic syndrome (mds) drugs market report here:

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-mds-drugs-global-market-report

Which Region Currently Holds The Largest Share Of The Myelodysplastic Syndrome (MDS) Drugs Market?

North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2025. The regions covered in the myelodysplastic syndrome (mds) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Myelodysplastic Syndrome (MDS) Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13043&type=smp

Browse Through More Reports Similar to the Global Myelodysplastic Syndrome (MDS) Drugs Market 2026, By The Business Research Company

Bone Marrow Transplantation Market Report 2026

https://www.thebusinessresearchcompany.com/report/bone-marrow-transplantation-global-market-report

Blood Transfusion Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report

Patient Blood Management Market Report 2026

https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795